HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device (AREDS)

The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)

The overall objective of this two arm randomized clinical trial (RCT) is to determine if home monitoring using the comprehensive visual field and telemedicine solution based on the ForeseeHome device in AREDS2 improves detection of progression to choroidal neovascularization (CNV) when compared with standard care.

Study Overview

• Status: Completed
• Conditions: Age Related Macular Degeneration
• Intervention / Treatment: Diagnostic test: ForeseeHome AMD Monitoring Device

Detailed Description

The overall objective of this two arm randomized clinical trial (RCT) is to determine if home monitoring using the comprehensive visual field and telemedicine solution based on the ForeseeHome device in AREDS2 (referred to as the ForeseeHome comprehensive solution) participants at high risk of progression to neovascular AMD improves detection of progression to choroidal neovascularization (CNV) when compared with standard care. The primary outcome of this study is presenting best corrected visual acuity (BCVA) at the time of CNV diagnosis. Secondary outcomes include time to confirmed CNV diagnosis, lesion size, lesion location (extrafoveal, juxtafoveal, or subfoveal), lesion type (occult without classic, predominantly classic or minimally classic), sensitivity and specificity, and BCVA following three consecutive months of treatment and twelve months after the initial start of CNV treatment with an intravitreal anti-VEGF agent using either ranibizumab or bevacizumab. Outcomes will be ascertained via the following specific aims:

• Study Type: Interventional
• Enrollment (Actual): 1520
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Arkansas
    • Little Rock, Arkansas, United States, 72205
      • Jones Eye Institute - UAMS
  • California
    • La Jolla, California, United States, 92093
      • Shiley Eye Center - UCSD
    • Loma Linda, California, United States, 92354
      • Loma Linda Univ.
    • Sacramento, California, United States, 95817
      • Univ. of California, Davis
  • Colorado
    • Denver, Colorado, United States, 80230
      • Colorado Retina Assoc.
    • Louisville, Colorado, United States, 80027
      • Eldorado Retina Associates
  • Connecticut
    • New Haven, Connecticut, United States
      • Yale Univ. Eye Center
  • Florida
    • Jacksonville, Florida, United States, 32209
      • Univ. of Florida Health Science Center
    • Miami, Florida, United States, 33136
      • Bascom Palmer Eye Institute
    • Sarasota, Florida, United States, 34239
      • Sarasota Retina Institute
  • Georgia
    • Atlanta, Georgia, United States, 30322
      • Emory Univ. Eye Center
    • Decatur, Georgia, United States, 30030
      • Georgia Retina, P.C.
  • Kentucky
    • Lexington, Kentucky, United States, 40509
      • Retina Associates of Kentucky
  • Maryland
    • Baltimore, Maryland, United States, 21237
      • Elman Retina Group, PA
    • Baltimore, Maryland, United States, 21287
      • Wilmer Eye Institute
    • Chevy Chase, Maryland, United States, 20815
      • Retina Group of Washington
  • Massachusetts
    • Boston, Massachusetts, United States
      • Ophthalmic Cons. of Boston
  • Michigan
    • Detroit, Michigan, United States, 48201
      • Kresge Eye Institute
    • Grand Rapids, Michigan, United States, 49546
      • Vision Research Foundation
    • Royal Oak, Michigan, United States, 48073
      • Vision Research Foundation
    • Traverse City, Michigan, United States, 49684
      • Vision Research Foundation
  • New Jersey
    • Lawrenceville, New Jersey, United States
      • Delaware Valley Retina Associates
  • New York
    • Slingerlands, New York, United States, 12159
      • Retina Research Foundation
  • North Carolina
    • Charlotte, North Carolina, United States, 28210
      • Charlotte Eye Ear Nose and Throat Assoc
    • Durham, North Carolina, United States, 27710
      • Duke Univ.
  • Ohio
    • Cleveland, Ohio, United States, 44106
      • Case Western Reserve Univ.
    • Cleveland, Ohio, United States, 44122
      • Retina Assoc. of Cleveland
  • Pennsylvania
    • Camp Hill, Pennsylvania, United States, 17011
      • Pennsylvania Retina Specialists, P.C.
    • Hershey, Pennsylvania, United States, 17033
      • Penn State M.S. Hershey Med Ctr
    • Philadelphia, Pennsylvania, United States, 19104
      • Scheie Eye Institute
    • Pittsburgh, Pennsylvania, United States, 15213
      • UPMC Eye Center
  • Tennessee
    • Memphis, Tennessee, United States, 38103
      • Univ. of Tennessee HSC
  • Texas
    • Dallas, Texas, United States, 75231
      • Texas Retina Associates
    • Houston, Texas, United States, 77030
      • Retina Consult. of Houston
    • Lubbock, Texas, United States, 79410
      • Texas Retina Associates
  • Utah
    • Salt Lake City, Utah, United States, 84132
      • John Moran Eye Center, Univ. of Utah
  • Wisconsin
    • Madison, Wisconsin, United States, 53705
      • Univ. of Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Medical College of Wisconsin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 55 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

INCLUSION CRITERIA:

• Male or female participant between 55 and 90 years of age. Participants must have bilateral large drusen (at least 125 micron), or large drusen in the posterior pole in one eye (study eye) and advanced AMD (neovascular AMD or central geographic atrophy) in the fellow eye as determined by their study ophthalmologist. Likelihood, willingness, and ability to return for multiple visits (potentially within the same month) for at least 2 years.
• Participant must be English speaking and understand and sign the protocol's informed consent document.
• Participant must be able to successfully demonstrate their ability to comprehend instructions and use of the ForeseeHome device (a ForeseeHome device will be available at the clinic for the participant to demonstrate their ability).
• Participant's address to which the ForeseeHome device will be sent, if randomized to the device monitoring arm, must be located in the U.S.A.
• Study eye(s) must have best corrected visual acuity 20/60 or better (at least 54 letters).
• Ocular media sufficient to allow adequate quality fundus photography.
• Participant must be willing to have name and contact information provided to Notal Vision.
• Participant must consent to be examined by the study ophthalmologist when changes in symptoms are detected by the home-device or by standard of care or when unreliable test results occur during the usage period.
• If randomized to the device monitoring arm, participant must agree to take the device with them if staying somewhere else other than their primary residence for 14 days or more.

EXCLUSION CRITERIA:

• Participant has evidence of macular or retinal disorders other than AMD in the study eye(s).
• Participant has known adverse reaction to fluorescein dye or refuses further fluorescein angiograms.
• Participant's eye is receiving (or is expected to receive) an eye examination on a continuing basis by an eye care professional more frequently than every four months
• NonAREDS2 participant currently enrolled in another study that may likely affect adherence with The HOME Study
• Previous retinal or other ocular surgical procedures, the effects of which may now or in the future complicate assessment of the progression of AMD in the study eye.
• Chronic requirement for any systemic or ocular medication administered for other diseases
• Cataract surgery within one month of randomization.
• Participant that has any condition that would make adherence to study follow up procedures for at least one year difficult or unlikely

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: ForeseeHome AMD Monitoring Device; Participants in the device monitoring arm will receive a packed device at home, with instructions to install and connect the device to a modem as well as instructions for daily use of the device in addition to standard care	Diagnostic test: ForeseeHome AMD Monitoring Device; Earlier detection of progression from intermediate dry age-related macular degeneration to CNV between routine eye exams through home diagnostic testing with the ForeseeHome AMD Monitoring device
No Intervention: Standard care alone (control) arm; Standard care instruction per clinic routine for home vision monitoring to detect progression of AMD and routine eye exams

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Outcome: Change in Visual Acuity (LogMAR Letters) From Baseline to Detection of Choroidal Neovascularization	Mean change in BCVA (logMAR letters) from baseline to the time of confirmed progression to CNV in the ForeseeHome device monitoring group compared to the standard care group.	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Secondary Outcome: Patients Who Maintained 20/40 or Better Vision at Time of CNV Detection	Percent of patients who maintained 20/40 or better vision at the time of CNV detection in each study arm	2 years
Secondary Outcome: Lesion Size (Total Lesion Area) at Time of Confirmed Progression to CNV	Median lesion size (total lesion area) at time of confirmed progression to CNV as measured on fluorescein angiography (FA) will be compared between the two study arms. Lesion size was assessed, measured, and reported by optic disc areas, where 1 disc area = 2.54 mm^2.	2 years
Secondary Outcome: Lesion Size (CNV Area) at Time of Confirmed Progression to CNV	Median lesion size (CNV area) at time of confirmed progression to CNV as measured on fluorescein angiography will be compared between the two study arms. Lesion size was assessed, measured, and reported by optic disc areas, where 1 disc area = 2.54 mm^2.	2 years
Secondary Outcome: Lesion Size (Fluid Area) at Time of Confirmed Progression to CNV	Median lesion size (fluid area) at time of confirmed progression to CNV as measured on fluorescein angiography will be compared between the two study arms. Lesion size was assessed, measured, and reported by optic disc areas, where 1 disc area = 2.54 mm^2.	2 years

Collaborators and Investigators

• Sponsor: Notal Vision Ltd.
• Investigators: Study Chair: Emily Chew, MD, National Eye Institute (NEI)

Publications and helpful links

Helpful Links

• Sponsor Home Page

Study record dates

Study Major Dates

• Study Start: May 1, 2010
• Primary Completion (Actual): October 1, 2013
• Study Completion (Actual): December 1, 2013

Study Registration Dates

• First Submitted: April 12, 2010
• First Submitted That Met QC Criteria: April 13, 2010
• First Posted (Estimate): April 14, 2010

Study Record Updates

• Last Update Posted (Actual): July 30, 2019
• Last Update Submitted That Met QC Criteria: July 16, 2019
• Last Verified: July 1, 2019

More Information

Terms related to this study

• Keywords: AMD; CNV
• Additional Relevant MeSH Terms: Eye Diseases; Retinal Degeneration; Retinal Diseases; Macular Degeneration
• Other Study ID Numbers: ForeseeHome AREDS2

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No